MA26649A1 - COMPOSITIONS COMPRENANT UN MODULATEUR DE RECEPTEUR D'OESTROGENE SELECTIF ET DE L'HORMONE PARATHYROiDIENNE, ET PROCÉDÉ POUR LEUR PREPARATION. - Google Patents

COMPOSITIONS COMPRENANT UN MODULATEUR DE RECEPTEUR D'OESTROGENE SELECTIF ET DE L'HORMONE PARATHYROiDIENNE, ET PROCÉDÉ POUR LEUR PREPARATION.

Info

Publication number
MA26649A1
MA26649A1 MA25623A MA25623A MA26649A1 MA 26649 A1 MA26649 A1 MA 26649A1 MA 25623 A MA25623 A MA 25623A MA 25623 A MA25623 A MA 25623A MA 26649 A1 MA26649 A1 MA 26649A1
Authority
MA
Morocco
Prior art keywords
modulator
compositions
preparation
estrogen receptor
parathyroid hormone
Prior art date
Application number
MA25623A
Other languages
English (en)
Inventor
Zhu Ke Hua
Duane Thompson David
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26649A1 publication Critical patent/MA26649A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
MA25623A 1998-06-16 1999-06-15 COMPOSITIONS COMPRENANT UN MODULATEUR DE RECEPTEUR D'OESTROGENE SELECTIF ET DE L'HORMONE PARATHYROiDIENNE, ET PROCÉDÉ POUR LEUR PREPARATION. MA26649A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8947998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
MA26649A1 true MA26649A1 (fr) 2004-12-20

Family

ID=22217879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25623A MA26649A1 (fr) 1998-06-16 1999-06-15 COMPOSITIONS COMPRENANT UN MODULATEUR DE RECEPTEUR D'OESTROGENE SELECTIF ET DE L'HORMONE PARATHYROiDIENNE, ET PROCÉDÉ POUR LEUR PREPARATION.

Country Status (34)

Country Link
US (1) US6132774A (fr)
EP (1) EP1094808A1 (fr)
JP (1) JP2002518323A (fr)
KR (1) KR20010052818A (fr)
CN (1) CN1305373A (fr)
AP (1) AP9901580A0 (fr)
AR (1) AR018867A1 (fr)
AU (1) AU3725999A (fr)
BG (1) BG105125A (fr)
BR (1) BR9911228A (fr)
CA (1) CA2335078A1 (fr)
CO (1) CO5070584A1 (fr)
EA (1) EA200001199A1 (fr)
GT (1) GT199900066A (fr)
HN (1) HN1999000063A (fr)
HR (1) HRP20000858A2 (fr)
HU (1) HUP0102759A3 (fr)
ID (1) ID26873A (fr)
IL (1) IL139588A0 (fr)
IS (1) IS5719A (fr)
MA (1) MA26649A1 (fr)
NO (1) NO20006313D0 (fr)
NZ (1) NZ508039A (fr)
OA (1) OA11566A (fr)
PA (1) PA8471201A1 (fr)
PE (1) PE20000644A1 (fr)
PL (1) PL344982A1 (fr)
SK (1) SK18922000A3 (fr)
TN (1) TNSN99119A1 (fr)
TR (1) TR200003567T2 (fr)
UA (1) UA60367C2 (fr)
WO (1) WO1999065482A1 (fr)
YU (1) YU75800A (fr)
ZA (1) ZA993972B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20030191096A1 (en) * 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
EP2428516A1 (fr) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
CN111067907A (zh) * 2018-10-18 2020-04-28 常州大学 孕激素在抑制血管内皮生长因子表达中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
NZ508039A (en) 2003-03-28
AR018867A1 (es) 2001-12-12
IS5719A (is) 2000-11-21
CO5070584A1 (es) 2001-08-28
IL139588A0 (en) 2002-02-10
PA8471201A1 (es) 2000-09-29
CN1305373A (zh) 2001-07-25
BG105125A (en) 2001-11-30
OA11566A (en) 2004-05-26
EA200001199A1 (ru) 2001-04-23
PE20000644A1 (es) 2000-08-02
PL344982A1 (en) 2001-11-19
HRP20000858A2 (en) 2001-10-31
UA60367C2 (uk) 2003-10-15
WO1999065482A1 (fr) 1999-12-23
US6132774A (en) 2000-10-17
CA2335078A1 (fr) 1999-12-23
BR9911228A (pt) 2001-02-13
GT199900066A (es) 2000-10-31
ZA993972B (en) 2000-12-15
AU3725999A (en) 2000-01-05
SK18922000A3 (sk) 2001-09-11
KR20010052818A (ko) 2001-06-25
YU75800A (sh) 2003-12-31
JP2002518323A (ja) 2002-06-25
TR200003567T2 (tr) 2001-06-21
TNSN99119A1 (fr) 2005-11-10
HUP0102759A2 (hu) 2002-03-28
ID26873A (id) 2001-02-15
NO20006313L (no) 2000-12-12
HN1999000063A (es) 2000-01-12
AP9901580A0 (en) 1999-06-30
HUP0102759A3 (en) 2002-12-28
NO20006313D0 (no) 2000-12-12
EP1094808A1 (fr) 2001-05-02

Similar Documents

Publication Publication Date Title
IL147485A0 (en) Pharmaceutical compositions containing a selective estrogen receptor modulator
ZA997733B (en) Hydrazide compounds, a process for their preparation and pharmaceutical compositions containing them.
HU9700777D0 (en) Estrogenic agents, process for producing them and pharmaceutical compositions containing them
HUP0002126A3 (en) Non-steroidal (hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity, process for their preparation and pharmaceutical compositions thereof
FR2779896B1 (fr) PROCEDE POUR PAYER A DISTANCE, AU MOYEN D'UN RADIOTELEPHONIQUE MOBILE, l'ACQUISITION D'UN BIEN ET/OU D'UN SERVICE ET SYSTEME ET RADIOTELEPHONE MOBILE CORRESPONDANTS
IL133575A0 (en) Sulfonamide compounds, a method for producing same and pharmaceutical compositions containing same
EP1017002A3 (fr) Méthode et système pour la distribution des contenus numeriques
FR2799554B1 (fr) Composition d'elimination de photoresist et procede pour eliminer un photoresist au moyen de cette composition
ZA200004548B (en) Process for preparing a spread.
HUP9802757A3 (en) New naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
DZ2032A1 (fr) Un procédé pour la préparation de l'hydrochlorure de lercanidipine.
GB9904021D0 (en) Polymer for photoresist,photoresist composition containing the same,and preparation method thereof
EP1120653A4 (fr) Procede visant a examiner une substance ayant une interaction avec un recepteur hormonal
ZA9811895B (en) Method and system for routing agent programs through a communications network.
ZA993972B (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone.
ZA986970B (en) Improved process for antiparasitic agent.
FR2760236B1 (fr) Calix (4) arenes-couronnes, leur procede de preparation et leur utilisation pour l'extraction selective du cesium
EP0579309A3 (fr) Procédé pour la préparation d'un matériau à base de ciment et composition de ciment contenant ce matériau.
FR2772380B1 (fr) Procede de preparation d'alkylmonohydrogenohalogenosilanes (ahhs) par redistribution puis distillation, dispositif pour la mise en oeuvre de ce procede
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
HUP0200481A2 (en) Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines, process for their preparation and pharmaceutical compositions containing them
HUP0003962A3 (en) Quinuclidinium compounds process for preparing thereof, pharmaceutical compositions comprising thereof, their use, and their intermediates
PL336206A1 (en) Method of preventing mammary carcinoma by means of selective modulators of oestrogen receptors
MA26436A1 (fr) Composes d'ammonium quaternaire, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2779606B1 (fr) Procede d'administration d'un reseau de stations de base